Skip to main content
SpringerLink
Log in

Clinical Applications of Commonly Used Contemporary Antidotes

A US Perspective

  • Review Articles
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Poisonings are a common problem. In 1995, over 2 million exposures were reported to American poison information centres alone. The majority of poisoning exposures can be treated without major therapeutic intervention. If therapy is indicated, it is usually in the form of gastrointestinal decontamination with activated charcoal, to prevent absorption of the toxin and the subsequent toxicity that may occur.

In a limited number of cases, more aggressive life-support measures may be necessary to treat the adverse effects of poisons. Occasionally, that intervention may include the use of pharmacological antagonists, more commonly referred to as antidotes.

According to the American Association of Poison Control Centers, the most commonly used antidotes are acetylcysteine, naloxone, atropine, deferoxamine (desferrioxamine) and antivenins. Overall, 17 antidotes account for 99% of all antidote use and those agents are reviewed in this article.

With the exception of naloxone, most antidotes have pharmacological effects that are independent of their inherent antidotal properties. Therefore, antidotes should be used judiciously because their pharmacological properties may exacerbate pre-existing toxicity and only in rare circumstances are they used prophylactically. Some antidotes, such as digoxin-specific antigen binding fragments (digoxin immune Fab), are very expensive, and both the risk: benefit ratio and the associated cost should be considered before the antidote is administered.

The principle aims are to ‘treat the patient, not the poison’ and to do no harm to the patient. Antidotes should be used only when they are indicated and may help a patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Litovitz TL, Felberg L, White S, et al. 1995 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1996; 14:487–537

    PubMed  CAS  Google Scholar 

  2. Litovitz TL, Felberg L, Soloway RA, et al. 1994 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1995; 13: 551–97

    PubMed  CAS  Google Scholar 

  3. Litovitz T, Veltri JC. 1984 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1985; 3: 423–50

    PubMed  CAS  Google Scholar 

  4. Litovitz TL, Normann SA, Veltri JC. 1985 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1986; 4: 427–58

    PubMed  CAS  Google Scholar 

  5. Litovitz TL, Martin TG, Schmitz B. 1986 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1987; 5: 405–45

    PubMed  CAS  Google Scholar 

  6. Litovitz TL, Schmitz BF, Matyunas N, et al. 1987 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1988; 6: 479–515

    PubMed  CAS  Google Scholar 

  7. Litovitz TL, Schmitz BF, Holm KC. 1988 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1989; 7: 495–545

    PubMed  CAS  Google Scholar 

  8. Litovitz TL, Schmitz BF, Bailey KM. 1989 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1990; 8: 394–442

    PubMed  CAS  Google Scholar 

  9. Litovitz TL, Bailey KM, Schmitz BF, et al. 1990 annual report of the American Association of Poison Control Centers National Data Collection system. Am J Emerg Med 1991; 9: 461–509

    PubMed  CAS  Google Scholar 

  10. Litovitz TL, Holm KC, Bailey KM, et al. 1991 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1992; 10: 452–505

    PubMed  CAS  Google Scholar 

  11. Litovitz TL, Holm KC, Clancy C, et al. 1992 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1993; 11: 494–555

    PubMed  CAS  Google Scholar 

  12. Litovitz TL, Clark LR, Soloway RA. 1993 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1994; 12: 546–84

    PubMed  CAS  Google Scholar 

  13. Veltri JC, Litovitz TL. 1983 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1984; 2: 420–43

    PubMed  CAS  Google Scholar 

  14. Krenzelok EP, Leikin JB. Approach to the poisoned patient. Dis Month 1996; 42: 511–607

    Google Scholar 

  15. Hoffman JR, Schringer DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med 1991; 20: 246–52

    PubMed  CAS  Google Scholar 

  16. Redbook®. Montvale, NJ: Medical Economics, 1995

  17. Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319: 1557–62

    PubMed  CAS  Google Scholar 

  18. Lewis RK, Paloucek FP. Assessment and treatment of acetaminophen overdose. Clin Pharm 1991; 10: 765–74

    PubMed  CAS  Google Scholar 

  19. Prescott LF, Roscoe P, Wright N, et al. Plasma paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet 1971; I: 519–22

    Google Scholar 

  20. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995; 346: 547–52

    PubMed  CAS  Google Scholar 

  21. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975; 55: 871–6

    PubMed  CAS  Google Scholar 

  22. Dey Laboratories, Inc. Mucosil product information. Napa, CA: Dey Laboratories, Inc., March 1991

    Google Scholar 

  23. Chamberlain JM, Gorman RL, Oderda GM, et al. Use of activated charcoal in a simulated poisoning with acetaminophen: a new loading dose for N-acetylcysteine?. Ann Emerg Med 1993; 22: 1398–402

    PubMed  CAS  Google Scholar 

  24. Smilkstein MJ. A new loading dose for N-acety Icysteine? The answer is no [correspondence]. Ann Emerg Med 1994; 24: 538–9

    PubMed  CAS  Google Scholar 

  25. Brent J. Are activated charcoal-N-acetylcysteine interactions of clinical significance?. Ann Emerg Med 1993; 22: 1860–1

    PubMed  CAS  Google Scholar 

  26. North DS, Peterson RG, Krenzelok EP. Effect of activated charcoal administration on acetylcysteine serum levels in humans. Am J Hosp Pharm 1981; 38: 1022–4

    PubMed  CAS  Google Scholar 

  27. Rybolt TR, Burrell DE, Shults JM, et al. In vitro coadsorption of acetaminophen and N-acetylcysteine onto activated carbon powder. J Pharm Sci 1986: 75: 904–6

    PubMed  CAS  Google Scholar 

  28. Rose SR. Subtleties of managing acetaminophen poisoning. Am J Hosp Pharm 1994; 51: 3065–8

    PubMed  CAS  Google Scholar 

  29. Flanagan RJ, Meredith TJ. Use of N-acetylcysteine in clinical toxicology. Am J Med 1991; 91 Suppl. 3C: 131S–9S

    PubMed  CAS  Google Scholar 

  30. Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous TV-acetylcysteine treatment protocol. Ann Emerg Med 1991; 20: 1058–63

    PubMed  CAS  Google Scholar 

  31. Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990; 335: 1572–3

    PubMed  CAS  Google Scholar 

  32. Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol-induced fulminant hepatic failure: a prospective controlled trial. Br Med J 1991; 303: 1026–9

    CAS  Google Scholar 

  33. Jaimovich DG. Transport management of the patient with acute poisoning. Pediatr Clin North Am 1993; 40: 407–30

    PubMed  CAS  Google Scholar 

  34. Alam SN, Roberts RJ, Fisher LJ. Age related differences in salicylamide and acetaminophen conjugation in man. J Pediatr 1977; 90: 130

    PubMed  CAS  Google Scholar 

  35. Peterson RG, Rumack BH. Age as a variable in acetaminophen overdose. Arch Intern Med 1981; 141: 390–3

    PubMed  CAS  Google Scholar 

  36. Peterson RG, Rumack BH. Pharmacokinetics of acetaminophen in children. Pediatrics 1978; 62: 877–9

    PubMed  CAS  Google Scholar 

  37. Fine JS, Goldfrank LR. Update in medical toxicology. Pediatr Clin North Am 1992; 39: 1031–51

    PubMed  CAS  Google Scholar 

  38. Fiser DH, Moss MM, Walker W. Critical care for clonidine poisoning in toddlers. Crit Care Med 1990; 18: 1124–8

    PubMed  CAS  Google Scholar 

  39. Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994; 12: 650–60

    PubMed  CAS  Google Scholar 

  40. Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979; 115: 1366–7

    PubMed  CAS  Google Scholar 

  41. Martin WR. Naloxone. Ann Intern Med 1976; 85: 765–8

    PubMed  CAS  Google Scholar 

  42. Wahlstrom A, Winblad B, Bixo M, et al. Human brain metabolism of morphine and naloxone. Pain 1988; 35: 121–7

    PubMed  CAS  Google Scholar 

  43. Litovitz TL. The anecdotal antidotes. Emerg Med Clin North Am 1984; 2: 145–58

    PubMed  CAS  Google Scholar 

  44. Lewis JM, Klein-Schwartz W, Benson BE. Continuous naloxone infusion in pediatric narcotic overdose. Am J Dis Child 1984; 138: 944–6

    PubMed  CAS  Google Scholar 

  45. Romac DR. Safety of prolonged, high-dose infusion of naloxone hydrochloride for severe methadone overdose. Clin Pharm 1986; 5: 251–4

    PubMed  CAS  Google Scholar 

  46. Goldfrank L, Weisman RS, Errick JK, et al. Ann Emerg Med 1986; 15: 566–70

    PubMed  CAS  Google Scholar 

  47. Bradberry JC, Raebel MA. Continuous infusion of naloxone in the treatment of narcotic overdose. Drug Intell Clin Pharm 1981; 15:945–50

    PubMed  CAS  Google Scholar 

  48. Osterwalder JJ. Naloxone — for intoxications with intravenous heroin and heroin mixtures — harmless or hazardous? A prospective clinical study. Clin Toxicol 1996; 34: 409–16

    CAS  Google Scholar 

  49. Cuss FM, Colaco CB, Baron JH. Cardiac arrest after reversal of effects of opiates with naloxone. Br Med J 1984; 288: 363–4

    CAS  Google Scholar 

  50. Neal JM, Owens BD, Wright SW. Hazards of antagonizing narcotic sedation with naloxone [letter]. Ann Emerg Med 1993; 22: 145–6

    PubMed  CAS  Google Scholar 

  51. Gremse DA, Artman M, Boerth RC. Hypertension associated with naloxone treatment for clonidine poisoning. J Pediatr 1986; 108: 776–8

    PubMed  CAS  Google Scholar 

  52. Powers RD, Donowitz LG. Endotracheal administration of emergency medications. South Med J 1984; 77: 340–1

    PubMed  CAS  Google Scholar 

  53. Tandberg D, Abercrombie D. Treatment of heroin overdose with endotracheal naloxone. Ann Emerg Med 1982; 11:443–5

    PubMed  CAS  Google Scholar 

  54. Doyon S, Roberts JR. Reappraisal of the ‘coma cocktail’: dextrose, flumazenil, naloxone and thiamine. Emerg Med Clin North Am 1994; 12:301–16

    PubMed  CAS  Google Scholar 

  55. Kaplan JL, Marx JA. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study. Ann Emerg Med 1993; 22: 187–90

    PubMed  CAS  Google Scholar 

  56. DeBleecker J, Van Den Neucker K, Willems J. The intermediate syndrome in organophosphate poisoning: presentation of a case and review of the literature. J Toxicol Clin Toxicol 1992; 30: 321–9; 331–2

    CAS  Google Scholar 

  57. DeBleecker J, Van Den Neucker K, Colardyn F. Intermediate syndrome in organophosphorus poisoning: a prospective study. Crit Care Med 1993; 21: 1706–11

    CAS  Google Scholar 

  58. Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides: an intermediate syndrome. N Engl J Med 1987; 316: 761–3

    PubMed  CAS  Google Scholar 

  59. Haddad LM. Organophosphate poisoning — intermediate syndrome [editorial]. Clin Toxicol 1992; 30: 331–2

    Google Scholar 

  60. Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993; 58:51–66

    PubMed  CAS  Google Scholar 

  61. Ellenhorn MJ, Barceloux DG. Medical toxicology: diagnosis and treatment of human poisoning. New York: Elsevier, 1988

    Google Scholar 

  62. Fuortes LJ, Ayebo AD, Kross BC. Cholinesterase-inhibiting insecticide toxicity. Am Fam Physician 1993; 15; 47: 1613–20

    PubMed  CAS  Google Scholar 

  63. Ali-Melkkila T, Kanto J, Lisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 1993; 37: 633–42

    PubMed  CAS  Google Scholar 

  64. Lotti M. Treatment of acute organophosphate poisoning. Med J Aust 1991; 154:51–5

    PubMed  CAS  Google Scholar 

  65. Orma PS, Middleton RK. Aerosolized atropine as an antidote to nerve gas. Ann Pharmacother 1992; 26: 937–8

    PubMed  CAS  Google Scholar 

  66. Rumack BH, Spoerke DG, editors. POISINDEX Information System. Denver, Colorado: MICROMEDEX, Inc., edition expires 31 August 1996

    Google Scholar 

  67. Bardin PG, van Eeden SF, Moolman JA, et al. Organophosphate and carbamate poisoning. Arch Intern Med 1994; 154: 1433–41

    PubMed  CAS  Google Scholar 

  68. Shockley LW. The use of inhaled nebulized atropine for the treatment of malathion poisoning. Clin Toxicol 1989; 27: 183–92

    CAS  Google Scholar 

  69. Mills KC, Curry SC. Acute iron poisoning. Emerg Med Clin North Am 1994; 12:397–413

    PubMed  CAS  Google Scholar 

  70. Swartz RD. Deferoxamine and aluminum removal. Am J Kidney Dis 1985; 6: 358–64

    PubMed  CAS  Google Scholar 

  71. Alfrey AC. Dialysis encephalopathy. Kidney Int 1986; 29 Suppl. 18: 53–7

    Google Scholar 

  72. Curry SC. Iron. In: Reisdorff EJ, Roberts MR, Wiegenstein JG, editors. Pediatric Emergency Medicine. Philadelphia: WB Saunders, 1993: 673–9

    Google Scholar 

  73. Fargion S, Taddei MT, Abutti V, et al. Early iron overload in beta-thalassaemia major: when to start chelation therapy?. Arch Dis Child 1982; 57: 929–33

    PubMed  CAS  Google Scholar 

  74. Pippard MJ. Desferrioxamine-induced iron excretion in humans. Bailliere’s Clin Haematol 1989: 2: 323–42

    CAS  Google Scholar 

  75. Falk RJ, Mattern WD, Lamanna RG, et al. Iron removal during C.A.P.D. using deferoxamine. Kidney Int 1983; 24: 110–2

    CAS  Google Scholar 

  76. Oliveri NF, Buncic R, Chew E, et al. Visual and auditory neurotoxicity n patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314: 869–73

    Google Scholar 

  77. Cheney K, Gumbiner C, Benson B, et al. Survival after a severe iron poisoning treated with intermittent infusions of deferoxamine. J Toxicol Clin Toxicol 1995; 33: 61–6

    PubMed  CAS  Google Scholar 

  78. Tenenbein M, Kowalski S, Sienko A, et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992; 339: 699–701

    PubMed  CAS  Google Scholar 

  79. Adamson IY, Sienko A, Tenenbein M. Pulmonary toxicity of deferoxamine in iron-poisoned mice. Toxicol Appl Pharmacol 1993; 120: 13–9

    PubMed  CAS  Google Scholar 

  80. Kirking MH. Treatment of chronic iron overload. Clin Pharm 1991; 10:775–83

    PubMed  CAS  Google Scholar 

  81. Turk J, Aks S, Ampuero F, et al. Successful therapy of iron intoxication in pregnancy with intravenous deferoxamine and whole bowel irrigation. Vet Hum Toxicol 1993; 35: 441–4

    PubMed  CAS  Google Scholar 

  82. Vaskaridou E, Konstantopoulos K, Kyriakou D, et al. Deferoxamine treatment during early pregnancy: absence of teratogenicity in two cases. Haematologica 1993; 78: 183–4

    PubMed  CAS  Google Scholar 

  83. Blake DR, Winyard P, Lunec J, et al. Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 1985; 219: 345–55

    Google Scholar 

  84. Banner W, Tong TG. Iron poisoning. Pediatr Clin North Am 1986; 33: 393–409

    PubMed  Google Scholar 

  85. Johnson CA. Management of snakebite. Am Fam Physician 1991; 44: 174–80

    PubMed  CAS  Google Scholar 

  86. Russel FE. Injuries by venomous animals [abstract]. Ann Intern Med 1964; 61: 803

    Google Scholar 

  87. Gold BS, Barish RA. Venomous snakebites: current concepts in diagnosis, treatment and management. Emerg Med Clin North Am 1992; 10:249–67

    PubMed  CAS  Google Scholar 

  88. Gold BS, Wingert WA. Snake venom poisoning in the US: a review of therapeutic practice. South Med J 1994; 87: 579–89

    PubMed  CAS  Google Scholar 

  89. Wyeth Laboratories, Inc. Antivenin (Crotalidae) Polyvalent (equine origin) product information. Marietta, PA: Wyeth Laboratories, Inc., 1986

    Google Scholar 

  90. Blackman JR, Dillon S. Venomous snakebite: past, present and future treatment options. J Am Board Fam Pract 1992; 5: 399–405

    PubMed  CAS  Google Scholar 

  91. Davidson TM, Schafer SF. Rattlesnake bites: guidelines for aggressive treatment. Postgrad Med 1994; 96: 107–14

    PubMed  CAS  Google Scholar 

  92. Schauben JL, Frenia ML. Update on antidotal therapy. J Pharm Pract 1993; 2: 63–73

    Google Scholar 

  93. Parrish HM, Kahn MS. Snakebite during pregnancy. Obstet Gynecol 1966; 27: 468–71

    PubMed  CAS  Google Scholar 

  94. Egen N, Russell F, Consroe P, et al. A new ovine Fab antivenom for north american venomous snakes [abstract]. Vet Hum Toxicol 1994; 36: 362

    Google Scholar 

  95. Dart RC, Siefert SA, Carroll L, et al. Human trial of an affinity purified antibody fragment for snake venom poisoning [abstract]. Vet Hum Toxicol 1994; 36: 363

    Google Scholar 

  96. Roche Laboratories. Romazicon™ product information. Nutley, NJ: Roche Laboratories, April 1993

    Google Scholar 

  97. Lheureux P, Debailleul G, De Witte O, et al. Zolpidem intoxication mimicking narcotic overdose: response to flumazenil. Hum Exp Toxicol 1990; 9: 105–7

    PubMed  CAS  Google Scholar 

  98. Hoffman EJ, Warren EW. Flumazenil: a benzodiazepine antagonist. Clin Pharm 1993; 12: 641–56

    PubMed  CAS  Google Scholar 

  99. Brogden RN, Goa KL. Flumazenil: a reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs 1991; 42: 1061–89

    PubMed  CAS  Google Scholar 

  100. Amrein R, Hetzel W, Hartman D, et al. Clinical pharmacology of flumazenil. Eur J Anaesthesiol 1988; 2 Suppl.: 65–80

    CAS  Google Scholar 

  101. Höjer J, Baehrendtz S, Magnusson A, et al. A placebo-controlled trial of flumazenil given by continuous infusion in severe benzodiazepine overdosage. Acta Anaesthesiol Scand 1991; 35: 584–90

    PubMed  Google Scholar 

  102. Clark RF, Sage TA, Tunget C, et al Delayed onset lorazepam poisoning successfully reversed by flumazenil in a child: case report and review of the literature. Pediatr Emerg Care 1995; 11 (1): 32–4

    PubMed  CAS  Google Scholar 

  103. The Flumazenil in Benzodiazepine Intoxication Multicenter Study Group. Treatment of benzodiazepine overdose with flumazenil. Clin Ther 1992; 14: 978–95

    Google Scholar 

  104. Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother 1994; 28: 1347–9

    PubMed  CAS  Google Scholar 

  105. Agency for Toxic Substances and Disease Registry (ATSDR), U.S. Department of Health and Human Services, Public Health Service. Case studies in environmental medicine: methanol toxicity. San Rafael, CA: DeLima Associates, July 1992

    Google Scholar 

  106. Burkhart KK, Kulig KW. The other alcohols: methanol, ethylene glycol, and isopropanol. Emerg Med Clin North Am 1990; 8:913–8

    PubMed  CAS  Google Scholar 

  107. Brown CG, Trumbull D, Klein-Schwartz W. Ethylene glycol poisoning. Ann Emerg Med 1983; 12: 501–6

    PubMed  CAS  Google Scholar 

  108. Berman LB, Schreiner GE, Feys J. The nephrotoxic lesion of ethylene glycol. Ann Intern Med 1957; 46: 611–9

    PubMed  CAS  Google Scholar 

  109. Factor SA, Lava NS. Ethylene glycol intoxication: a new stage in the clinical syndrome. NY State J Med 1987; 87: 179–80

    CAS  Google Scholar 

  110. Kruse JA. Methanol poisoning. Intensive Care Med 1992; 18: 391–7

    PubMed  CAS  Google Scholar 

  111. Bolgiano EB, Barish RA. Use of new and established antidotes. Emerg Med Clin North Am 1994; 12: 317–34

    PubMed  CAS  Google Scholar 

  112. DaRoza R, Henning RJ, Sunshine I, et al Acute ethylene glycol poisoning. Crit Care Med 1984; 12 (11): 1003–5

    PubMed  CAS  Google Scholar 

  113. McCoy HG, Cipolle RJ, Ehlers SM, et al. Severe methanol poisoning: application of a pharmacokinetic model for ethanol therapy and hemodialysis. Am J Med 1979; 67: 804–7

    PubMed  CAS  Google Scholar 

  114. Manoguerra AS, Cipolle RJ, Zaske DE, et al. Serum concentration studies during hemodialysis in a patient with severe methanol intoxication. In: Rumack BH, Temple AR, editors. Management of the Poisoned Patient. Princeton: Science Press, 1977: 103–14

    Google Scholar 

  115. Gonda A, Gault H, Churchill D, et al. Hemodialysis for methanol intoxication. Am J Med 1978; 64: 749–58

    PubMed  CAS  Google Scholar 

  116. Osterloh JD, Pond SM, Grady S, et al. Serum formate concentrations in methanol intoxication as a criteria for hemodialysis. Ann Intern Med 1986: 104: 200–3

    PubMed  CAS  Google Scholar 

  117. Jacobsen D, Sebastian CS, Barron SK, et al. Effects of 4-methylpyrazole, methanol/ethylene glycol antidote in healthy humans. J Emerg Med 1990; 8: 455–61

    PubMed  CAS  Google Scholar 

  118. Jobard E, Harry P, Turcant A, et al. 4-Methylpyrazole and hemodialysis in ethylene glycol poisoning. Clin Toxicol 1996; 34: 373–7

    CAS  Google Scholar 

  119. Jacobsen D, McMartin K. 4-Methylpyrazole — present status [editorial]. Clin Toxicol 1996; 34: 379–81

    CAS  Google Scholar 

  120. Yen D, Tsai J, Wang LM, et al. The clinical experience of acute cyanide poisoning. Am J Emerg Med 1995; 13: 524–8

    PubMed  CAS  Google Scholar 

  121. Kulling P. Hospital treatment of victims exposed to combustion products. Toxicol Lett 1992; 64–5: 283–9

    Google Scholar 

  122. Houeto P, Borron SW, Sandouk P, et al. Pharmacokinetics of hydroxocobalamin in smoke inhalation victims. Clin Toxicol 1996; 34: 397–404

    CAS  Google Scholar 

  123. Zerbe NF, Wagner BK. Use of vitamin B12 in the treatment and prevention of nitroprusside-induced cyanide toxicity. Crit Care Med 1993; 21: 465–7

    PubMed  CAS  Google Scholar 

  124. Forsyth JC, Mueller PD, Becker CE, et al. Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. J Toxicol Clin Toxicol 1993; 31: 277–94

    PubMed  CAS  Google Scholar 

  125. Kulig K. Cyanide antidotes and fire toxicology [editorial]. N Engl J Med 1991; 325: 1801–2

    PubMed  CAS  Google Scholar 

  126. Baud FJ, Barriot P, Toffis V, et al. Elevated blood cyanide concentrations in victims of smoke inhalation. N Engl J Med 1991; 325: 1761–6

    PubMed  CAS  Google Scholar 

  127. Buck ML, Reed MD. Use of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients. Clin Pharm 1991; 10: 32–48

    PubMed  CAS  Google Scholar 

  128. Somani SM, Dube SN. Physostigmine — an overview as pretreatment drug for organophosphate intoxication. Int J Clin Pharmacol Ther Toxicol 1989; 27: 367–87

    PubMed  CAS  Google Scholar 

  129. Edwards CC. Fight to save FDA and Commissioner Edwards depends on House Commerce Committee commitment to Representative Moss’ consumer product bill in conference clash with Magnuson’s Senate bill. FDC Reports 1972; 34: 21

    Google Scholar 

  130. Buzello W. Postoperative care: antagonism of drugs used in anaesthesia: muscle relaxants. Acta Anaesthesiol Scand 1988; 32 Suppl. 87: 25–7

    Google Scholar 

  131. Wachtel RE. Comparison of anticholinesterases and their effects on acetylcholine-activated ion channels. Anesthesiology 1990; 72: 496–503

    PubMed  CAS  Google Scholar 

  132. Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics 1973; 52: 449–51

    PubMed  CAS  Google Scholar 

  133. Feldman MD. The syndrome of anticholinergic intoxication. Am Fam Physician 1986; 34: 113–6

    PubMed  CAS  Google Scholar 

  134. Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med 1980; 9: 588–90

    PubMed  CAS  Google Scholar 

  135. Smolinske SC. Review of parenteral sulfite reactions. J Toxicol Clin Toxicol 1992; 20: 597–606

    Google Scholar 

  136. Ayerst Laboratories Inc. Protopam product information. New York, NY: Ayerst Laboratories Inc., 1991

    Google Scholar 

  137. Namba T, Nolte CR, Jackrel J, et al. Poisoning due to organophosphate insecticides. Am J Med 1971; 37: 475–92

    Google Scholar 

  138. Wadia RS, Amin RB. Fenthion poisoning [letter]. J Pediatr 1988; 113 (5): 950

    PubMed  CAS  Google Scholar 

  139. De Kort WLAM, Kiestra SH, Sangster B. The use of atropine and oximes in organophosphate intoxications: a modified approach. Clin Toxicol 1988; 26: 199–208

    Google Scholar 

  140. Kurtz PH. Pralidoxime in the treatment of carbamate intoxication. Am J Emerg Med 1990; 8: 68–70

    PubMed  CAS  Google Scholar 

  141. Leikin JB, Paloucek FP. Poisoning & toxicology handbook. Hudson, OH: Lexi-Comp, 1995: 1411–4

    Google Scholar 

  142. Taboulet P, Baud FJ, Bismuth C Clinical features and management of digitalis poisoning — rationale for immunotherapy. J Toxicol Clin Toxicol 1993; 31 (2): 247–60

    PubMed  CAS  Google Scholar 

  143. Smith TW, Butler Jr VP, Haber E. Cardiac glycoside-specific antibodies in the treatment of digitalis intoxication. In: Krause R, Haber E, editors. Antibodies in human diagnosis and therapy. New York: Raven Books, 1977: 365–89

    Google Scholar 

  144. Hoffman BF, Bigger Jr JT. Digitalis and allied cardiac glycosides. In: Gilman AG, Rail TW, Nies AS, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. Elmsford, New York: Pergamon Press, 1990: 815–39

    Google Scholar 

  145. Baud FJ, Bismuth C, Pontal PG, et al. Time course of antidigoxin Fab fragments and plasma digitoxin concentrations in an acute digitalis intoxication. J Toxicol Clin Toxicol 1983; 19: 857–60

    Google Scholar 

  146. Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991; 17: 590–8

    PubMed  CAS  Google Scholar 

  147. Woolf A. Revising the management of digitalis poisoning [editorial]. J Toxicol Clin Toxicol 1993; 31: 275–6

    PubMed  CAS  Google Scholar 

  148. Mauskopf JA, Wenger TW. Cost-effectiveness analysis of the use of digoxin immune Fab (Ovine) for treatment of digoxin toxicity. Am J Cardiol 1991; 68: 1709–14

    PubMed  CAS  Google Scholar 

  149. Centers for Disease Control/American Thoracic Society. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993 May 21; 42: 1–8

    Google Scholar 

  150. Dutt AK, Stead WW. Tuberculosis. Clin Geriatr Med 1992; 8: 761–75

    PubMed  CAS  Google Scholar 

  151. Dhennin C, Vesin L, Feauveaux J. Burns and the toxic effects of a derivative of hydrazine. Burns Incl Therm Inj 1988; 14: 130–4

    PubMed  CAS  Google Scholar 

  152. Boehnert MT, Lewander WJ, Gaudreault P, et al. Advances in clinical toxicology. Pediatr Clin North Am 1985; 32: 193–211

    PubMed  CAS  Google Scholar 

  153. Shah BR, Santucci K, Sinert R, et al. Acute isoniazid neurotoxicity in an urban hospital. Pediatrics 1995; 95: 700–4

    PubMed  CAS  Google Scholar 

  154. Siefkin AD, Albertson TE, Corbett MG. Isoniazid overdose: pharmacokinetics and effects of oral charcoal in treatment. Hum Toxicol 1987; 6: 497–501

    PubMed  CAS  Google Scholar 

  155. Yarbrough BE, Wood JP. Isoniazid overdose treated with highdose pyridoxine. Ann Emerg Med 1983; 12: 303–5

    PubMed  CAS  Google Scholar 

  156. Sievers ML, Herrier RN. Treatment of acute isoniazid toxicity. Am J Hosp Pharm 1975; 32: 202–6

    PubMed  CAS  Google Scholar 

  157. Vasile A, Goldberg R, Kornberg B. Pyridoxine toxicity: report of a case. J Am Osteopath Assoc 1984; 83: 790–1

    PubMed  CAS  Google Scholar 

  158. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med 1983; 309: 445–8

    PubMed  CAS  Google Scholar 

  159. Dalton K, Dalton JY. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand 1987; 76: 8–11

    PubMed  CAS  Google Scholar 

  160. Kutt H, Brennan R, Dehejia H, et al. Diphenylhydantoin intoxication. Am Rev Respir Dis 1970; 101: 377–84

    PubMed  CAS  Google Scholar 

  161. Glotzer DE, Freedberg KA, Bauchner H. Management of childhood lead poisoning: clinical impact and cost-effectiveness. Med Decis Making 1995; 15: 13–24

    PubMed  CAS  Google Scholar 

  162. Mortensen ME, Walson PD. Chelation therapy for childhood lead poisoning. Clin Pediatr 1993; 32: 284–91

    CAS  Google Scholar 

  163. Glotzer DE. Management of childhood lead poisoning. Pediatr Ann 1994; 23: 606–15

    PubMed  CAS  Google Scholar 

  164. Gelman CR, Rumack BH, editors. DRUGDEX Information System. Denver, Colorado: MICROMEDEX, Inc., (edition expired 31 August, 1996)

  165. Clarkson TW. Mercury — an element of mystery [editorial]. N Engl J Med 1990; 323: 1137–8

    PubMed  CAS  Google Scholar 

  166. Kosnett MJ. Unanswered question in metal chelation. J Toxicol Clin Toxicol 1992; 30: 529–47

    PubMed  CAS  Google Scholar 

  167. Levy RS, Fisher M, Alter JN. Penicillamine: review and cutaneous manifestations. J Am Acad Dermatol 1983: 8: 548–88

    PubMed  CAS  Google Scholar 

  168. Liebelt EL, Shannon MW. Oral chelators for childhood lead poisoning. Pediatr Ann 1994; 11: 616–9, 623–6

    Google Scholar 

  169. Watson WS, Hume R, Moore MR Oral absorption of lead and iron. Lancet 1980; 2 (8188): 236–7

    PubMed  CAS  Google Scholar 

  170. Markowitz ME, Rosen JF, Bijur PE. Effects of iron deficiency on lead excretion in children with moderate lead intoxication. J Pediatr 1990; 116:360–4

    PubMed  CAS  Google Scholar 

  171. Rodriguez LF, Smolik LM, Zbehlik AJ. Benzocaine-induced methemoglobinemia: report of a severe reaction and review of the literature. Ann Pharmacother 1994; 28: 643–9

    PubMed  CAS  Google Scholar 

  172. Scott EM. Congenital methemoglobinemia due to DPNH-dis-phorase deficiency. In: Buetler E, editor. Hereditary disorders of erythrocyte metabolism. New York: Grune and Stratton, 1968: 102

    Google Scholar 

  173. Truman TL, Dallessio JJ, Weibley RE. Life-threatening Pyridium Plus intoxication: a case report. Pediatr Emerg Care 1994; 10: 225–8

    PubMed  CAS  Google Scholar 

  174. Sills MR, Zinkham WH. Methylene blue-induced heinz body hemolytic anemia. Arch Pediatr Adolesc Med 1994; 148:306–10

    PubMed  CAS  Google Scholar 

  175. Foxworth JW, Roberts JA, Mahmoud SE Acquired methemoglobinemia: a case report. Mo Med 1987; 84: 187–9

    PubMed  CAS  Google Scholar 

  176. Hall AH, Rumack BH. Clinical toxicology of cyanide. Ann Emerg Med 1986; 15: 1067

    PubMed  CAS  Google Scholar 

  177. Jones J, McMullen MJ, Dougherty J. Toxic smoke inhalation: cyanide poisoning in fire victims. Am J Emerg Med 1987; 5: 318–21

    Google Scholar 

  178. Johnson WS, Hall AH, Rumack BH. Cyanide poisoning successfully treated without ‘therapeutic methemoglobin levels’. Am J Emerg Med 1989; 7: 437–40

    PubMed  CAS  Google Scholar 

  179. Hall AH, Kulig KW, Rumack BH. Toxic smoke inhalation [editorial]. Am J Emerg Med 1989; 7: 121–2

    PubMed  CAS  Google Scholar 

  180. Kirk MA, Gerace R, Kulig KW. Cyanide and methemoglobin kinetics in smoke inhalation victims treated with the cyanide antidote kit. Ann Emerg Med 1993; 22: 1413–8

    PubMed  CAS  Google Scholar 

  181. Mann KV, Travers JD. Succimer: an oral lead chelator. Clin Pharm 1991; 10:914–22

    PubMed  CAS  Google Scholar 

  182. McNeil Consumer Products Company. Chemet product information. Fort Washington, PA: McNeil Consumer Products Company, 1994

    Google Scholar 

  183. Wegmann K. Chelation therapy to treat lead toxicity in children. Minn Med 1992; 75: 25–7

    PubMed  CAS  Google Scholar 

  184. Goldfrank LR. Medical toxicology. JAMA 1992; 268: 375–6

    PubMed  CAS  Google Scholar 

  185. Graziano JF, Siris ES, Lolacono N, et al. 2,3 dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther 1985; 37: 431–8

    PubMed  CAS  Google Scholar 

  186. Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology 1995; 97: 23–38

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy Department, The Methodist Hospital, Houston, Texas, USA

    Carol A. Bowden

  2. Pittsburgh Poison Center, Children’s Hospital of Pittsburgh, Schools of Pharmacy and Medicine, University of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, Pennsylvania, 15213, USA

    Edward P. Krenzelok

Authors
  1. Carol A. Bowden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward P. Krenzelok
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bowden, C.A., Krenzelok, E.P. Clinical Applications of Commonly Used Contemporary Antidotes. Drug-Safety 16, 9–47 (1997). https://doi.org/10.2165/00002018-199716010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199716010-00002

Keywords

Search

Navigation